Li P, Selvaraj P, Zhu C
George W. Woodruff School of Mechanical Engineering and Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332-0363, USA.
Biophys J. 1999 Dec;77(6):3394-406. doi: 10.1016/S0006-3495(99)77171-7.
Binding of the Fc portion of IgG coated on targets to Fcgamma receptors (e.g., CD16) expressed on leukocytes (i.e., 2D binding) is an initiating step for immune responses such as phagocytosis or antibody-dependent cellular cytotoxicity. In vivo, circulating leukocytes are exposed to plasma IgG. The competition from soluble IgG (i.e., 3D binding) may affect the 2D binding. Many cell surface receptors, CD16 included, have soluble counterparts. While their physiological significance is not clear, receptor-based competitive inhibition therapy, in which soluble receptors, ligands, and their analogs are employed to compete with surface-bound receptors and ligands to prevent unwanted adhesion, is widely used to treat various diseases. To provide a quantitative basis for design of these therapeutic approaches, we developed a mathematical model for 2D and 3D competition binding. The model relates cell-surface adhesion (in the presence and absence of dislodging forces) to the concentration of the soluble competitor, the densities of the surface-bound receptors and ligands, as well as the binding affinities of the 2D and 3D interactions. Binding of CD16-expressing cells to an IgG-coated surface in the presence of a soluble competitor (IgG or anti-CD16 antibody) was quantified by a centrifugation assay. The agreement between experiment and theory supports the validity of the model, which could be useful in predicting the efficacy of the competitor.
包被在靶标上的IgG的Fc部分与白细胞上表达的Fcγ受体(如CD16)的结合(即二维结合)是吞噬作用或抗体依赖性细胞毒性等免疫反应的起始步骤。在体内,循环白细胞会接触血浆IgG。可溶性IgG的竞争(即三维结合)可能会影响二维结合。许多细胞表面受体,包括CD16,都有可溶性对应物。虽然它们的生理意义尚不清楚,但基于受体的竞争性抑制疗法,即使用可溶性受体、配体及其类似物与表面结合的受体和配体竞争以防止不必要的黏附,被广泛用于治疗各种疾病。为了为这些治疗方法的设计提供定量依据,我们开发了一个二维和三维竞争结合的数学模型。该模型将细胞表面黏附(在存在和不存在解吸附力的情况下)与可溶性竞争者的浓度、表面结合的受体和配体的密度以及二维和三维相互作用的结合亲和力联系起来。通过离心测定法定量表达CD16的细胞在可溶性竞争者(IgG或抗CD16抗体)存在下与IgG包被表面的结合。实验与理论之间的一致性支持了该模型的有效性,该模型可用于预测竞争者的疗效。